The expert panel evaluated the eye-health ingredient in accordance with FDA guidelines and found that it met the safety criteria.
Photo © iStockphoto.com/kutaytanir
OmniActive Health Technologies (Morristown, NJ) has received a notification from a panel confirming the Generally Recognized as Safe (GRAS) status of its OmniXan-RS meso-zeaxanthin ingredient. The expert panel evaluated the eye-health ingredient in accordance with FDA guidelines and found that it met safety criteria. According to the company, the OmniXan-RS ingredient (meso-zeaxanthin, or 3R,3’S zeaxanthin) is made from marigold flower and is grown and extracted through a vertically integrated supply chain. “With the rising interest and science supporting meso-zeaxanthin, OmniXan-RS helps meet a gap for a standalone RS-zeaxanthin ingredient in the market,” said Lynda M. Doyle, senior vice president of global marketing, OmniActive, in a press release. “Like most of the ingredients in our portfolio, we obtained GRAS self-affirmation to further position OmniXan-RS as unique and safe.” In addition to OmniXan-RS, the company’s range of macular carotenoids includes Lutemax 2020 lutein with enhanced zeaxanthin, Lutemax Free lutein, and OmniXan RR-zeaxanthin, made from natural paprika. Also read: Kemin's ZeaOne Zeaxanthin Gets FDA GRAS Lutein and Zeaxanthin Elicit "Rapid Retinal Response," Study Suggests The Blue-Light Message: Explaining the Benefits of Lutein and Zeaxanthin
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.